WCM Investment Management
ACAD icon

WCM Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

WCM Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-286,527
Closed -$4.5M – 289
2024
Q3 		$4.5M Sell
286,527
-2,890
-1% -$48.2K 0.01% 169
2024
Q2 		$4.74M Buy
289,417
+7,382
+3% +$119K 0.01% 164
2024
Q1 		$5.21M Buy
+282,035
New +$6.99M 0.01% 160
2021
Q2 		– Sell
-129,864
Closed -$3.35M – 196
2021
Q1 		$3.35M Buy
129,864
+56,330
+77% +$2.48M 0.01% 145
2020
Q4 		$3.93M Buy
73,534
+415
+0.6% +$20.6K 0.01% 148
2020
Q3 		$3.02M Buy
73,119
+3,349
+5% +$145K 0.01% 150
2020
Q2 		$3.38M Sell
69,770
-27,891
-29% -$1.34M 0.01% 143
2020
Q1 		$4.13M Buy
97,661
+28,235
+41% +$1.16M 0.02% 120
2019
Q4 		$2.97M Buy
69,426
+56,750
+448% +$2.47M 0.02% 137
2019
Q3 		$456K Buy
+12,676
New +$384K ﹤0.01% 144

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

WCM Investment Management's ACAD Position: Q4 2024 in Review

WCM Investment Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2024, closing a stake of 286,527 shares — an estimated $4.5M sold.

WCM Investment Management first reported a position in ACAD in Q3 2019 and held it in 10 quarters. The position peaked at $5.21M in Q1 2024. 296 funds tracked by Wall St. Rank hold ACAD as of Q4 2024.

  • WCM Investment Management reported no remaining Acadia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • WCM Investment Management sold 286,527 Acadia Pharmaceuticals shares in Q4 2024, an estimated $4.5M.
  • WCM Investment Management first reported a position in Acadia Pharmaceuticals in Q3 2019 and held it in 10 quarters.
  • WCM Investment Management's Acadia Pharmaceuticals position peaked at $5.21M in Q1 2024.
  • 296 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2024.

Based on WCM Investment Management's 13F filing for Q4 2024, filed 28 Jan 2025.